Rob Bresnahan
Rob Bresnahan (R-PA) bought $1K-$15K of $ABBV (AbbVie Inc. Common Stock (ABBV)) on May 15, 2025, part of 54 transactions in this filing (28 buys, 26 sells).
HillSignal flagged 5 timing concerns on this filing — trades that line up closely with related legislative or contract activity.
Price Movement Since Trade
How the largest positions have moved from the trade date to the most recent close.
Showing the 6 largest positions. See every transaction in the table below.
Suspicious Timing Detected
5 flagsRob Bresnahan bought $1,001 - $15,000 in $NVDA on May 12, 2025, May 13, 2025, and May 16, 2025 — 6 to 10 days before the Access Technology Affordability Act of 2025 (S1918) was introduced, a bill that could benefit the company.
Rob Bresnahan bought $1,001 - $15,000 in $MSFT on May 9, 2025 — 12 days before HR67 ("Modernizing Retrospective Regulatory Review") was introduced, a bill that could create new procurement opportunities for government tech solutions.
Rob Bresnahan sold $1,001 - $15,000 in $CNC and HUM on May 15, 2025 — 6 days before the Association Health Plans Act (S1847) was introduced, a bill that aims to increase competition for large health insurers.
These flags identify timing coincidences between stock trades and legislative activity. They do not imply wrongdoing. Click any bill number or ticker to see the full analysis.
Share This Filing
All Transactions
| Type | Ticker | Asset | Amount | Trade Price | Current | Change | Date |
|---|---|---|---|---|---|---|---|
| BUY | $ABBV | AbbVie Inc. Common Stock (ABBV) | $1K-$15K | $181.68 | $198.69 | +9.4% | May 15, 2025 |
| BUY | $APD | Air Products and Chemicals, Inc. Common Stock (APD) | $1K-$15K | $274.42 | — | — | May 15, 2025 |
| BUY | $BAX | Baxter International Inc. Common Stock (BAX) | $1K-$15K | $31.04 | $18.16 | -41.5% | May 15, 2025 |
| BUY | $BDX | Becton, Dickinson and Company Common Stock (BDX) | $1K-$15K | $135.43 | — | — | May 15, 2025 |
| BUY | $BIIB | Biogen Inc. - Common Stock (BIIB) | $1K-$15K | $123.70 | — | — | May 15, 2025 |
| BUY | $DXCM | DexCom, Inc. - Common Stock (DXCM) | $1K-$15K | $85.67 | — | — | May 15, 2025 |
| BUY | $DOW | Dow Inc. Common Stock (DOW) | $1K-$15K | $29.90 | — | — | May 15, 2025 |
| BUY | $EOG | EOG Resources, Inc. Common Stock (EOG) | $1K-$15K | — | — | — | May 15, 2025 |
| BUY | $IDXX | IDEXX Laboratories, Inc. - Common Stock (IDXX) | $1K-$15K | $511.99 | — | — | May 15, 2025 |
| BUY | $JPM | JP Morgan Chase & Co. Common Stock (JPM) | $1K-$15K | $267.49 | — | — | May 15, 2025 |
Connected Legislative Activity
10 signalsThese bills and contracts share tickers or sectors with this filing's trades.
Stop the Scroll Act
The Stop the Scroll Act (S.1885) is a bearish catalyst for ad-revenue-dependent social media platforms. Despite recent rallies, this bill mandates FTC/Surgeon General warning labels on platforms like those owned by META, SNAP, and PINS. Real market data shows META dropped -10.36% in the past 7 days, while SNAP and PINS remain off their 52-week highs, indicating market sensitivity to regulatory risk.
DeOndra Dixon INCLUDE Project Act of 2025
HR3491 (DeOndra Dixon INCLUDE Project Act) authorizes a Down syndrome research program at NIH but appropriates zero funding. With only 5 procedural actions over a year and stalled committee markup, the bill has no near-term market impact. No public companies are directly affected.
Improving Seniors’ Timely Access to Care Act of 2025
The Improving Seniors' Timely Access to Care Act mandates electronic prior authorization for all Medicare Advantage plans by 2028, forcing a regulatory-driven health IT spending wave. Oracle (ORCL) is the clearest beneficiary as dominant EHR vendor, while major MA insurers (UNH, ELV, HUM, CVS) face mandated IT investment but gain long-term operational efficiency. The bill has strong bipartisan momentum with 68 cosponsors and an identical House companion.
Small Biotech Innovation Act
The Small Biotech Innovation Act (HR3731) is an early-stage bill that would exempt R&D-intensive small biotech manufacturers (≤5 qualifying drugs) from Medicare drug price negotiations starting in 2029. The bill is in committee with no floor action, and no market reaction is evident from provided data. The legislative path is long and uncertain — this is a structural watch item, not a trading catalyst.
Association Health Plans Act
S.1847 is an early-stage bill expanding self-funded association health plans for small businesses, structurally negative for fully insured commercial carriers. The bill has no dollar authorization and remains in committee with only 6 sponsors — near-term passage probability is low. Real market data shows large health insurers (UNH, HUM, CVS, CNC) surging 15-55% in the last 30 days, but this rally is unrelated to S.1847 and driven by broader sector dynamics.
Modernizing Retrospective Regulatory Review
HR67 mandates federal agencies adopt AI-driven regulatory review tools, creating a new procurement category that benefits established FedRAMP-authorized cloud providers. The bill is pure authorization with no direct appropriations, but structural adoption requirements generate recurring revenue for $ORCL, $IBM, and $MSFT. Partner AI providers (e.g., Palantir, C3.ai) are secondary beneficiaries with lower confidence.
Access Technology Affordability Act of 2025
S. 1918 is an early-stage, low-probability bill proposing a refundable tax credit for blind individuals purchasing access technology. It creates no direct revenue stream for any public company and has negligible near-term market impact.
Streamlining Federal Cybersecurity Regulations Act of 2025
S.1875 is an early-stage procedural bill to create an interagency committee for harmonizing federal cybersecurity regulations. It contains no funding, no mandates, and no procurement directives. Near-term market impact is negligible.
To provide for a limitation on the transfer of defense articles and defense services to Israel.
HR3565, a bill restricting the transfer of specific bombs and artillery ammunition to Israel, is in early legislative stages but introduces headline risk for defense primes with Israeli exposure. Actual market data shows LMT down 15.87% over 30 days, RTX down 9.55%, and defense stocks broadly under pressure, though this is only one factor among many. The bill faces an uphill path through committee and full chambers, but the restriction mechanism is specific and actionable.
SEPSIS Act
The SEPSIS Act (S.1929) is an early-stage authorization bill that would create federal programs for sepsis research, education, and data collection. It authorizes but does not appropriate funding, and with only 6 cosponsors and referral to committee in June 2025, passage remains uncertain. Real market data shows all four diagnostic/lab stocks have declined 1-6% in the past week and 2-10% over 30 days, reflecting broader market pressure on healthcare despite the legislative catalyst.
Other Filings by Rob Bresnahan
Free — no credit card
Get the next Bresnahan trade the day it's disclosed
HillSignal tracks every Congressional stock filing and federal contract, scores its market impact with AI, and emails you the ones that matter — before they hit the news.
Weekly digest — the congressional activity that actually moved markets that week, in plain English. Free, one email.
Free forever plan · No credit card · Unsubscribe in one click
Want the live terminal too? Create a free account →
Data sourced from the U.S. House of Representatives Office of the Clerk Financial Disclosure system. Stock prices from Financial Modeling Prep. Suspicious timing flags identify coincidences between stock trades and legislative activity and do not imply any wrongdoing or illegal activity. This is not financial advice.